These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 23292973)
1. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents. Clark BA; Sessink PJ J Oncol Pharm Pract; 2013 Jun; 19(2):99-104. PubMed ID: 23292973 [TBL] [Abstract][Full Text] [Related]
2. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device. Siderov J; Kirsa S; McLauchlan R J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949 [TBL] [Abstract][Full Text] [Related]
3. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Harrison BR; Peters BG; Bing MR Am J Health Syst Pharm; 2006 Sep; 63(18):1736-44. PubMed ID: 16960258 [TBL] [Abstract][Full Text] [Related]
4. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device. Guillemette A; Langlois H; Voisine M; Merger D; Therrien R; Mercier G; Lebel D; Bussières JF J Oncol Pharm Pract; 2014 Dec; 20(6):426-32. PubMed ID: 24395542 [TBL] [Abstract][Full Text] [Related]
5. Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs. Bartel SB; Tyler TG; Power LA Am J Health Syst Pharm; 2018 Feb; 75(4):199-211. PubMed ID: 29339374 [TBL] [Abstract][Full Text] [Related]
6. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. Sessink PJ; Connor TH; Jorgenson JA; Tyler TG J Oncol Pharm Pract; 2011 Mar; 17(1):39-48. PubMed ID: 20156932 [TBL] [Abstract][Full Text] [Related]
7. Comparative parallel assessment of a transfer device in reducing 5-fluorouracil environmental contamination inside positive air pressure isolators. Forges F; Simoens X; Chauvin F J Oncol Pharm Pract; 2011 Mar; 17(1):61-7. PubMed ID: 20699332 [TBL] [Abstract][Full Text] [Related]
8. Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation. Sessink PJ; Leclercq GM; Wouters DM; Halbardier L; Hammad C; Kassoul N J Oncol Pharm Pract; 2015 Apr; 21(2):118-27. PubMed ID: 24567041 [TBL] [Abstract][Full Text] [Related]
9. Syringe plunger contamination by hazardous drugs: a comparative study. Smith ST; Szlaczky MC J Oncol Pharm Pract; 2014 Oct; 20(5):381-5. PubMed ID: 24598373 [TBL] [Abstract][Full Text] [Related]
10. A new, validated wipe-sampling procedure coupled to LC-MS analysis for the simultaneous determination of 5-fluorouracil, doxorubicin and cyclophosphamide in surface contamination. Bobin-Dubigeon C; Amiand M; Percheron C; Audeval C; Rochard S; Leynia P; Bard JM J Anal Toxicol; 2013 Sep; 37(7):433-9. PubMed ID: 23828102 [TBL] [Abstract][Full Text] [Related]
11. Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning. Chu WC; Hon CY; Danyluk Q; Chua PP; Astrakianakis G J Oncol Pharm Pract; 2012 Mar; 18(1):46-51. PubMed ID: 21737485 [TBL] [Abstract][Full Text] [Related]
12. The assessment of environmental and external cross-contamination in preparing ready-to-administer cytotoxic drugs: a comparison between a robotic system and conventional manual production. Werumeus Buning A; Geersing TH; Crul M Int J Pharm Pract; 2020 Feb; 28(1):66-74. PubMed ID: 31489970 [TBL] [Abstract][Full Text] [Related]
13. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Yoshida J; Tei G; Mochizuki C; Masu Y; Koda S; Kumagai S Ann Occup Hyg; 2009 Mar; 53(2):153-60. PubMed ID: 19261696 [TBL] [Abstract][Full Text] [Related]
14. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Wick C; Slawson MH; Jorgenson JA; Tyler LS Am J Health Syst Pharm; 2003 Nov; 60(22):2314-20. PubMed ID: 14652980 [TBL] [Abstract][Full Text] [Related]
15. Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process. Valero S; López-Briz E; Vila N; Solana A; Melero M; Poveda JL Regul Toxicol Pharmacol; 2018 Jun; 95():1-7. PubMed ID: 29510165 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator. Vyas N; Turner A; Clark JM; Sewell GJ J Oncol Pharm Pract; 2016 Feb; 22(1):10-9. PubMed ID: 25073678 [TBL] [Abstract][Full Text] [Related]
17. Development of a closed drug preparation method for oral anticancer drugs. Wakui N; Ookubo T; Iwasaki Y; Ito R; Saito K; Nakazawa H J Oncol Pharm Pract; 2013 Dec; 19(4):315-20. PubMed ID: 23292970 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding. Soefje S; Rickabaugh K; Rajkumar R; Wall KP Int J Pharm Compd; 2021; 25(6):515-522. PubMed ID: 34807847 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding. Soefje S; Rickabaugh K; Rajkumar R; Wall KP Int J Pharm Compd; 2022; 26(1):72-79. PubMed ID: 35081047 [TBL] [Abstract][Full Text] [Related]
20. [Determination of airborne and surface contamination with cyclophosphamide at the Masaryk Memorial Cancer Institute, Brno, Czech Republic]. Gorná L; Odráska P; Dolezalová L; Piler P; Oravec M; Bláha L Ceska Slov Farm; 2011 Feb; 60(1):25-31. PubMed ID: 21650015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]